(NASDAQ:SMMT) () CEO Glyn Edwards caught up with Proactive Investors at the BIO CEO & Investor Conference in New York.
Edwards says the company expects to begin treating its first patient this quarter in its Phase 3 study of ridinilazol.
Summit is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE